IP Library Granted Patent US 8,278,291
Granted Patent B1
US 8,278,291 · App. 10/049,968 · Granted Oct 2, 2012

Treatment of wrinkles and strias with 4-hydroxyandrostenedione or a derivative thereof

Assignee: Curadis GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,291
App. No.
10/049,968
Granted
Oct 2, 2012
Kind
B1
Abstract

The invention relates to the treatment of wrinkles in the face, wrinkles at open-necked regions, pregnancy strias, and stretched strias on the lower abdomen, thighs or buttocks with a steroidal aromatase inhibitor which also has 5-alpha reductase inhibitor activity which is 4-hydroxyandrostenedione or a derivative thereof.

Claims (9)

1. A cosmetic treatment comprising the steps of:

identifying a subject suffering from a condition selected from the group consisting of wrinkles in the face, wrinkles at open-necked regions, pregnancy strias, and stretched strias on the lower abdomen, thighs or buttocks; and

administering a pharmaceutical composition comprising a steroidal aromatase inhibitor which also has 5-alpha-reductase inhibitor activity to said subject in an amount sufficient to alleviate at least one symptom of said condition wherein said steroidal aromatase inhibitor which also has 5-alpha reductase inhibitor activity is 4-hydroxyandrostenedione or a derivative thereof.

2. The cosmetic treatment method of claim 1 , wherein the steroidal aromatase inhibitor is 4-hydroxyandrost-4-ene-3,17-dione.

3. The cosmetic treatment method of claim 1 , wherein the pharmaceutical composition comprises between about 0.001 and about 5% by weight of said steroidal aromatase inhibitor.

4. The cosmetic treatment method of claim 2 , wherein the pharmaceutical composition comprises between about 0.001 and about 5% by weight of said steroidal aromatase inhibitor.

5. The cosmetic treatment method of claim 3 , wherein the pharmaceutical composition is topically administered.

6. The cosmetic treatment method of claim 4 , wherein the pharmaceutical composition is topically administered.

7. The cosmetic treatment method of claim 1 , wherein the steroidal aromatase inhibitor is 4-acetyoxy-4androstene-3,17-dione.

Assignments (9)
COURT PROCEEDING REGARDING MDI ONCOLOGY, INC. AND DR. ALFRED SCHMIDT DATED SEPTEMBER 17, 2008 Recorded Nov 27, 2012
From: SCHMIDT, ALFRED, DR.
To: MDI ONCOLOGY, INC.
Reel/Frame 029358/0635 →
COURT PROCEEDING REGARDING MDI ONCOLOGY, INC. AND DR. ALFRED SCHMIDT DATED AUGUST 16, 2012 Recorded Nov 27, 2012
From: SCHMIDT, ALFRED, DR.
To: MDI ONCOLOGY, INC.
Reel/Frame 029358/0742 →
COURT PROCEEDING REGARDING MDI ONCOLOGY, INC. AND DR. ALFRED SCHMIDT DATED MARCH 26, 2009 Recorded Nov 27, 2012
From: SCHMIDT, ALFRED, DR.
To: MDI ONCOLOGY, INC.
Reel/Frame 029358/0457 →
CHANGE OF NAME Recorded Nov 9, 2012
From: MEDICAL DISCOVERIES, INC.
To: GLOBAL CLEAN ENERGY HOLDINGS, INC.
Reel/Frame 029268/0745 →
SALE AND PURCHASE AGREEMENT Recorded Nov 9, 2012
From: GLOBAL CLEAN ENERGY HOLDINGS, INC.; MDI ONCOLOGY, INC.
To: CURADIS GMBH
Reel/Frame 029275/0688 →
CHANGE OF NAME Recorded Nov 5, 2012
From: MEDICAL DISCOVERIES, INC.; GLOBAL CLEAN ENERGY HOLDINGS, INC.
To: MEDICAL DISCOVERIES, INC.; GLOBAL CLEAN ENERGY HOLDINGS, INC.
Reel/Frame 029237/0761 →
SALE AND PURCHASE AGREEMENT Recorded Nov 5, 2012
From: GLOBAL CLEAN ENERGY HOLDINGS, INC.; MDI ONCOLOGY, INC.; CURADIS GMBH
To: GLOBAL CLEAN ENERGY HOLDINGS, INC.; MDI ONCOLOGY, INC.; CURADIS GMBH
Reel/Frame 029244/0572 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2005
From: SAVETHERAPEUTICS, A.G.
To: MEDICAL DISCOVERIES, INC.
Reel/Frame 016631/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2005
From: WIELAND, DR. HEINRICH
To: SAVETHERAPEUTICS, AG
Reel/Frame 016616/0260 →
Priority Claims (1)
DE 199 38 421 · Aug 13, 1999 · national